Haemonetics (HAE) Financials

$62.59 -1.26 (-1.97%)

Closing price 03:59 PM Eastern

Extended Trading

$62.52 -0.07 (-0.11%)

As of 06:26 PM Eastern

Annual Income Statements for Haemonetics

This table shows Haemonetics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	3/28/2015	4/2/2016	4/1/2017	3/31/2018	3/30/2019	3/28/2020	4/3/2021	4/2/2022	4/1/2023	3/30/2024
Net Income / (Loss) Attributable to Common Shareholders	17	-56	-26	46	55	77	79	43	115	118
Consolidated Net Income / (Loss)	17	-56	-26	46	55	77	79	43	115	118
Net Income / (Loss) Continuing Operations	17	-56	-26	46	55	77	79	43	115	118
Total Pre-Tax Income	31	-53	-27	60	74	87	73	64	141	152
Total Operating Income	41	-44	-19	56	84	103	90	81	156	165
Total Gross Profit	434	406	378	412	418	485	398	506	615	692
Total Revenue	910	909	886	904	968	988	870	993	1,169	1,309
Operating Revenue	910	909	886	904	968	988	870	993	1,169	1,309
Total Cost of Revenue	476	503	508	492	550	504	473	488	554	618
Operating Cost of Revenue	476	503	508	492	550	504	473	488	554	618
Total Operating Expenses	394	450	398	356	334	381	308	425	459	527
Selling, General & Admin Expense	337	317	302	317	273	282	275	340	377	432
Research & Development Expense	54	45	38	39	36	31	33	47	50	54
Amortization Expense	-	-	-	-	25	26	33	47	33	32
Other Operating Expenses / (Income)	-	-	-	-	0.00	-8.08	-33	-9.60	-0.38	-2.00
Impairment Charge	5.44	92	59	0.00	0.00	51	-	0.00	0.00	10
Total Other Income / (Expense), net	-9.38	-9.47	-8.10	3.48	-9.91	-16	-17	-17	-15	-13
Other Income / (Expense), net	-9.38	-9.47	-8.10	3.48	-9.91	-16	-17	-17	-15	-13
Income Tax Expense	14	2.16	-1.21	14	19	11	-6.56	20	26	34
Basic Earnings per Share	$0.33	($1.09)	($0.51)	$0.86	$1.07	$1.51	$1.57	$0.85	$2.27	$2.32
Weighted Average Basic Shares Outstanding	51.53M	50.91M	51.52M	52.76M	51.53M	50.69M	50.69M	51.05M	50.78M	50.71M
Diluted Earnings per Share	$0.32	($1.09)	($0.51)	$0.85	$1.04	$1.48	$1.55	$0.84	$2.24	$2.29
Weighted Average Diluted Shares Outstanding	52.09M	50.91M	51.52M	53.50M	52.94M	51.82M	51.29M	51.35M	51.42M	51.40M
Weighted Average Basic & Diluted Shares Outstanding	51.20M	51M	51.50M	53M	51.21M	50.39M	50.95M	51.28M	50.54M	50.84M

This table shows Haemonetics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	7/2/2022	10/1/2022	12/31/2022	4/1/2023	7/1/2023	9/30/2023	12/30/2023	3/30/2024	6/29/2024	9/28/2024	12/28/2024
Net Income / (Loss) Attributable to Common Shareholders	20	33	33	29	41	25	31	20	38	34	37
Consolidated Net Income / (Loss)	20	33	33	29	41	25	31	20	38	34	37
Net Income / (Loss) Continuing Operations	20	33	33	29	41	25	31	20	38	34	37
Total Pre-Tax Income	25	41	42	33	52	33	44	23	47	45	50
Total Operating Income	31	47	43	35	54	35	46	30	40	52	59
Total Gross Profit	142	158	159	156	167	171	178	176	175	187	194
Total Revenue	261	297	305	304	311	318	336	343	336	346	349
Operating Revenue	261	297	305	304	311	318	336	343	336	346	349
Total Cost of Revenue	119	140	147	148	144	148	158	167	161	158	155
Operating Cost of Revenue	119	140	147	148	144	148	158	167	161	158	155
Total Operating Expenses	111	111	115	121	114	135	132	146	135	136	135
Selling, General & Admin Expense	92	92	95	98	93	115	112	122	108	107	106
Research & Development Expense	11	11	13	16	13	13	13	16	14	17	16
Amortization Expense	8.37	8.22	8.08	7.97	7.47	7.22	6.91	10	12	12	12
Total Other Income / (Expense), net	-5.27	-5.67	-1.06	-2.63	-2.07	-2.47	-1.95	-6.53	6.96	-6.99	-9.11
Other Income / (Expense), net	-5.27	-5.67	-1.06	-2.63	-2.07	-2.47	-1.95	-6.53	6.96	-6.99	-9.11
Income Tax Expense	5.62	7.86	9.28	3.24	11	7.92	13	3.05	8.34	11	12
Basic Earnings per Share	$0.39	$0.65	$0.65	$0.58	$0.81	$0.49	$0.62	$0.40	$0.75	$0.66	$0.75
Weighted Average Basic Shares Outstanding	51.22M	50.95M	50.51M	50.78M	50.54M	50.73M	50.77M	50.71M	50.94M	50.90M	50.29M
Diluted Earnings per Share	$0.38	$0.64	$0.64	$0.58	$0.80	$0.48	$0.61	$0.40	$0.74	$0.66	$0.74
Weighted Average Diluted Shares Outstanding	51.68M	51.56M	51.22M	51.42M	51.34M	51.40M	51.45M	51.40M	51.56M	51.24M	50.64M
Weighted Average Basic & Diluted Shares Outstanding	51.32M	50.61M	50.45M	50.54M	50.71M	50.74M	50.79M	50.84M	51.18M	50.22M	50.24M

This table details how cash moves in and out of Haemonetics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	3/28/2015	4/2/2016	4/1/2017	3/31/2018	3/30/2019	3/28/2020	4/3/2021	4/2/2022	4/1/2023	3/30/2024
Net Change in Cash & Equivalents	-32	-46	24	41	-11	-32	55	67	25	-106
Net Cash From Operating Activities	127	122	160	220	159	158	109	172	273	182
Net Cash From Continuing Operating Activities	127	122	160	220	159	158	109	172	273	182
Net Income / (Loss) Continuing Operations	17	-56	-26	46	55	77	79	43	115	118
Consolidated Net Income / (Loss)	17	-56	-26	46	55	77	79	43	115	118
Depreciation Expense	86	90	90	89	109	110	84	98	93	97
Amortization Expense	-	-	-	-	-	0.60	0.56	3.40	1.97	6.52
Non-Cash Adjustments To Reconcile Net Income	25	121	96	7.91	40	60	23	22	26	46
Changes in Operating Assets and Liabilities, net	-0.72	-34	0.39	78	-46	-89	-78	5.89	36	-86
Net Cash From Investing Activities	-122	-105	-73	-63	-116	-57	-425	-86	-144	-322
Net Cash From Continuing Investing Activities	-122	-105	-73	-63	-116	-57	-425	-86	-144	-322
Purchase of Property, Plant & Equipment	-122	-102	-76	-75	-119	-49	-37	-97	-110	-66
Acquisitions	0.00	-3.00	-	0.00	0.00	-35	-435	-2.50	-2.85	-244
Purchase of Investments	-	-	-	-	-	-	0.00	0.00	-33	-16
Sale of Property, Plant & Equipment	0.45	0.64	2.82	2.76	2.81	17	1.82	2.02	1.61	1.81
Divestitures	-	0.00	0.00	9.00	0.00	9.81	45	11	0.85	1.50
Net Cash From Financing Activities	-33	-63	-60	-121	-51	-131	367	-16	-100	38
Net Cash From Continuing Financing Activities	-33	-63	-60	-121	-51	-131	367	-16	-100	38
Repayment of Debt	-9.58	-22	-93	-62	-267	-13	-35	-18	-61	-72
Repurchase of Common Equity	-39	-61	0.00	-100	-160	-175	0.00	0.00	-75	0.00
Issuance of Debt	1.40	2.27	0.00	0.67	363	45	440	0.00	330	110
Other Financing Activities, net	14	18	33	40	13	12	-37	1.76	-295	0.48
Effect of Exchange Rate Changes	-4.06	-0.01	-1.57	3.94	-3.32	-1.87	4.18	-2.98	-3.94	-3.19
Cash Interest Paid	8.50	8.51	7.85	7.66	13	13	7.82	6.19	14	21
Cash Income Taxes Paid	11	7.83	6.96	9.08	8.21	12	12	24	18	53

This table details how cash moves in and out of Haemonetics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	7/2/2022	10/1/2022	12/31/2022	4/1/2023	7/1/2023	9/30/2023	12/30/2023	3/30/2024	6/29/2024	9/28/2024	12/28/2024
Net Change in Cash & Equivalents	-45	26	-17	60	1.25	65	-157	-15	166	-45	22
Net Cash From Operating Activities	42	87	64	80	19	99	-0.54	64	-27	49	44
Net Cash From Continuing Operating Activities	42	87	64	80	19	99	-0.54	64	-27	49	44
Net Income / (Loss) Continuing Operations	20	33	33	29	41	25	31	20	38	34	37
Consolidated Net Income / (Loss)	20	33	33	29	41	25	31	20	38	34	37
Depreciation Expense	22	23	24	24	23	23	24	28	29	29	29
Amortization Expense	0.80	-0.48	0.79	0.87	0.00	-	-	4.13	5.24	3.74	3.34
Non-Cash Adjustments To Reconcile Net Income	3.22	6.38	9.50	7.37	4.99	21	11	7.83	-16	12	3.27
Changes in Operating Assets and Liabilities, net	-4.35	25	-2.39	18	-50	30	-67	4.12	-85	-30	-29
Net Cash From Investing Activities	-58	-31	-37	-18	-15	-25	-269	-13	-139	-23	-17
Net Cash From Continuing Investing Activities	-58	-31	-37	-18	-15	-25	-269	-13	-139	-23	-17
Purchase of Property, Plant & Equipment	-45	-36	-17	-12	-7.68	-9.11	-15	-9.69	-5.66	-9.43	-8.55
Purchase of Investments	-10	-3.00	-20	-	-6.00	-1.00	-3.13	-5.42	-0.54	-9.83	-3.18
Sale of Property, Plant & Equipment	0.50	7.04	0.16	-6.09	0.40	0.52	0.34	0.55	20	0.19	0.25
Other Investing Activities, net	-	-	-	-	-1.98	-16	-7.65	-	-4.21	-2.54	-5.90
Net Cash From Financing Activities	-23	-26	-50	-1.60	-0.60	-7.17	109	-64	334	-75	1.38
Net Cash From Continuing Financing Activities	-23	-26	-50	-1.60	-0.60	-7.17	109	-64	334	-75	1.38
Repayment of Debt	-4.39	277	-332	-1.76	-2.61	-3.51	-3.45	-64	-10	-65	-187
Other Financing Activities, net	-19	-278	2.08	0.16	2.02	-3.67	2.88	0.11	-356	0.21	3.09
Effect of Exchange Rate Changes	-4.93	-4.03	4.57	0.46	-1.97	-1.53	3.02	-2.70	-1.45	4.20	-6.21

This table presents Haemonetics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	3/28/2015	4/2/2016	4/1/2017	3/31/2018	3/30/2019	3/28/2020	4/3/2021	4/2/2022	4/1/2023	3/30/2024
Total Assets	1,485	1,319	1,239	1,237	1,275	1,267	1,820	1,860	1,935	2,196
Total Current Assets	558	488	510	521	576	604	694	756	770	769
Cash & Equivalents	161	115	140	180	169	137	192	259	284	179
Accounts Receivable	146	157	153	151	185	165	128	159	179	207
Inventories, net	211	187	177	161	194	270	323	293	259	317
Prepaid Expenses	40	29	41	29	27	31	51	44	47	66
Plant, Property, & Equipment, net	322	338	324	332	344	253	218	258	311	311
Total Noncurrent Assets	606	493	405	384	355	410	909	845	854	1,115
Goodwill	334	268	211	211	211	211	466	467	466	565
Intangible Assets	245	204	178	157	128	133	365	310	276	406
Noncurrent Deferred & Refundable Income Taxes	16	7.06	3.99	3.96	4.36	3.93	6.01	4.47	5.24	7.74
Other Noncurrent Operating Assets	11	14	12	12	12	62	71	63	107	136
Total Liabilities & Shareholders' Equity	1,485	1,319	1,239	1,237	1,275	1,267	1,820	1,860	1,935	2,196
Total Liabilities	659	598	499	485	607	680	1,088	1,110	1,117	1,236
Total Current Liabilities	189	186	211	385	236	275	253	442	252	300
Short-Term Debt	22	43	61	194	28	77	17	214	12	10
Accounts Payable	48	40	43	55	63	51	50	58	64	73
Current Employee Benefit Liabilities	51	36	44	70	53	49	48	49	64	81
Other Current Liabilities	68	67	64	66	92	98	139	121	112	136
Total Noncurrent Liabilities	471	412	288	100	371	405	835	668	865	935
Long-Term Debt	406	365	254	59	322	306	691	559	754	798
Noncurrent Deferred & Payable Income Tax Liabilities	33	21	12	6.53	20	11	44	29	36	63
Other Noncurrent Operating Liabilities	32	26	22	34	29	89	100	80	75	75
Total Equity & Noncontrolling Interests	826	722	740	752	668	587	732	749	818	960
Total Preferred & Common Equity	826	722	740	752	668	587	732	749	818	960
Total Common Equity	826	722	740	752	668	587	732	749	818	960
Common Stock	427	440	483	504	537	554	603	573	595	635
Retained Earnings	420	316	290	267	161	79	158	202	253	360
Accumulated Other Comprehensive Income / (Loss)	-22	-35	-33	-19	-30	-45	-30	-26	-30	-36

This table presents Haemonetics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	1/1/2022	7/2/2022	10/1/2022	12/31/2022	7/1/2023	9/30/2023	12/30/2023	6/29/2024	9/28/2024	12/28/2024
Total Assets	1,831	1,821	1,865	1,878	1,962	2,011	2,200	2,541	2,525	2,531
Total Current Assets	729	688	716	706	802	866	765	979	956	1,006
Cash & Equivalents	237	215	241	224	286	351	194	344	299	321
Accounts Receivable	155	146	172	181	177	174	212	201	214	212
Inventories, net	306	278	255	256	289	286	304	374	382	360
Prepaid Expenses	32	48	48	45	50	55	55	59	61	113
Plant, Property, & Equipment, net	239	288	308	313	304	308	319	302	300	286
Total Noncurrent Assets	863	844	841	859	856	838	1,117	1,260	1,269	1,239
Goodwill	468	466	465	466	466	465	555	613	616	605
Intangible Assets	324	303	293	284	268	251	429	495	488	466
Noncurrent Deferred & Refundable Income Taxes	6.05	4.55	4.28	4.84	4.88	4.75	5.07	9.37	9.08	8.00
Other Noncurrent Operating Assets	65	71	80	103	117	117	127	142	156	160
Total Liabilities & Shareholders' Equity	1,831	1,821	1,865	1,878	1,962	2,011	2,200	2,541	2,525	2,531
Total Liabilities	1,101	1,050	1,136	1,102	1,098	1,118	1,257	1,636	1,646	1,624
Total Current Liabilities	355	180	262	227	237	264	262	260	274	253
Short-Term Debt	144	6.85	58	9.95	14	14	14	5.11	5.43	5.08
Accounts Payable	51	58	61	64	78	80	57	77	69	63
Current Employee Benefit Liabilities	39	30	45	52	33	46	59	41	49	46
Other Current Liabilities	121	85	98	101	112	125	132	137	150	139
Total Noncurrent Liabilities	745	870	874	875	861	853	995	1,376	1,372	1,371
Long-Term Debt	633	763	760	757	751	749	857	1,218	1,220	1,220
Noncurrent Deferred & Payable Income Tax Liabilities	26	33	36	40	37	35	62	65	63	61
Other Noncurrent Operating Liabilities	86	74	78	78	72	70	76	92	90	90
Total Equity & Noncontrolling Interests	731	770	729	776	865	894	943	905	879	907
Total Preferred & Common Equity	731	770	729	776	865	894	943	905	879	907
Total Common Equity	731	770	729	776	865	894	943	905	879	907
Common Stock	567	581	565	588	610	617	628	561	545	570
Retained Earnings	193	222	204	224	284	309	340	387	369	392
Accumulated Other Comprehensive Income / (Loss)	-29	-33	-40	-36	-30	-33	-24	-43	-35	-56

This table displays calculated financial ratios and metrics derived from Haemonetics' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	3/28/2015	4/2/2016	4/1/2017	3/31/2018	3/30/2019	3/28/2020	4/3/2021	4/2/2022	4/1/2023	3/30/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-3.00%	-0.17%	-2.50%	2.01%	7.04%	2.16%	-11.94%	14.10%	17.67%	12.01%
EBITDA Growth	-0.78%	-68.87%	70.59%	139.14%	22.95%	8.19%	-20.34%	4.45%	43.63%	7.99%
EBIT Growth	-14.38%	-271.40%	48.56%	317.03%	23.48%	18.36%	-16.34%	-12.73%	122.23%	7.40%
NOPAT Growth	-50.97%	-239.94%	55.89%	416.34%	45.46%	45.37%	7.79%	-43.73%	131.33%	0.23%
Net Income Growth	-51.93%	-428.93%	52.74%	273.49%	20.73%	39.09%	3.85%	-45.42%	166.05%	1.87%
EPS Growth	-52.24%	-440.63%	53.21%	266.67%	22.35%	42.31%	4.73%	-45.81%	166.67%	2.23%
Operating Cash Flow Growth	-8.85%	-4.18%	31.08%	37.94%	-27.71%	-0.67%	-31.23%	58.32%	58.51%	-33.44%
Free Cash Flow Firm Growth	-63.19%	310.31%	78.99%	52.78%	-69.83%	169.56%	-395.87%	112.15%	137.50%	-277.05%
Invested Capital Growth	0.95%	-7.22%	-9.83%	-9.70%	2.75%	-1.93%	49.82%	1.33%	2.84%	22.28%
Revenue Q/Q Growth	-1.58%	1.78%	-1.59%	0.61%	1.65%	-1.08%	-1.52%	4.19%	3.49%	3.06%
EBITDA Q/Q Growth	-0.52%	-32.91%	-44.99%	96.92%	9.13%	-0.14%	-26.08%	39.06%	7.45%	-0.84%
EBIT Q/Q Growth	-0.30%	-50.52%	-217.20%	563.45%	13.06%	0.16%	-40.37%	204.37%	13.94%	-5.72%
NOPAT Q/Q Growth	-43.82%	-63.64%	-160.38%	492.40%	19.34%	-2.13%	-19.23%	26.15%	17.90%	-4.56%
Net Income Q/Q Growth	-43.70%	-11.67%	-262.78%	361.19%	19.44%	-4.03%	-26.51%	91.98%	20.51%	-7.12%
EPS Q/Q Growth	-44.83%	-10.10%	-259.38%	342.86%	20.93%	-2.63%	-26.89%	95.35%	21.08%	-7.29%
Operating Cash Flow Q/Q Growth	3.11%	-1.66%	-10.47%	11.68%	-18.85%	19.46%	-29.19%	62.88%	4.42%	-7.87%
Free Cash Flow Firm Q/Q Growth	414.00%	-37.61%	-0.29%	5.16%	-35.52%	2.06%	-413.61%	109.94%	51.56%	3.31%
Invested Capital Q/Q Growth	-3.88%	-2.60%	-6.43%	-1.84%	1.99%	1.52%	48.46%	-0.60%	-1.47%	-1.91%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	47.72%	44.66%	42.71%	45.57%	43.15%	49.02%	45.70%	50.90%	52.63%	52.83%
EBITDA Margin	12.88%	4.02%	7.03%	16.47%	18.92%	20.03%	18.12%	16.59%	20.25%	19.53%
Operating Margin	4.45%	-4.84%	-2.19%	6.21%	8.63%	10.46%	10.31%	8.13%	13.35%	12.60%
EBIT Margin	3.42%	-5.88%	-3.10%	6.60%	7.61%	8.82%	8.38%	6.41%	12.10%	11.60%
Profit (Net Income) Margin	1.86%	-6.12%	-2.96%	5.04%	5.69%	7.74%	9.13%	4.37%	9.87%	8.98%
Tax Burden Percent	54.22%	104.05%	95.60%	76.42%	74.72%	87.81%	108.99%	68.17%	81.61%	77.41%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	45.78%	0.00%	0.00%	23.58%	25.28%	12.19%	-8.99%	31.83%	18.39%	22.59%
Return on Invested Capital (ROIC)	2.02%	-2.92%	-1.41%	4.93%	7.46%	10.80%	9.41%	4.39%	9.94%	8.84%
ROIC Less NNEP Spread (ROIC-NNEP)	0.04%	-11.78%	-6.83%	7.07%	1.63%	4.12%	4.58%	2.12%	7.54%	7.02%
Return on Net Nonoperating Assets (RNNOA)	0.01%	-4.26%	-2.19%	1.18%	0.29%	1.40%	2.64%	1.47%	4.79%	4.39%
Return on Equity (ROE)	2.03%	-7.18%	-3.60%	6.11%	7.75%	12.20%	12.05%	5.86%	14.73%	13.22%
Cash Return on Invested Capital (CROIC)	1.08%	4.57%	8.93%	15.13%	4.75%	12.74%	-30.48%	3.07%	7.14%	-11.21%
Operating Return on Assets (OROA)	2.08%	-3.81%	-2.15%	4.82%	5.86%	6.86%	4.72%	3.46%	7.45%	7.35%
Return on Assets (ROA)	1.13%	-3.96%	-2.05%	3.68%	4.38%	6.02%	5.15%	2.36%	6.08%	5.69%
Return on Common Equity (ROCE)	2.03%	-7.18%	-3.60%	6.11%	7.75%	12.20%	12.05%	5.86%	14.73%	13.22%
Return on Equity Simple (ROE_SIMPLE)	2.05%	-7.70%	-3.55%	6.06%	8.24%	13.03%	10.86%	5.79%	14.11%	12.25%
Net Operating Profit after Tax (NOPAT)	22	-31	-14	43	62	91	98	55	127	128
NOPAT Margin	2.41%	-3.38%	-1.53%	4.75%	6.45%	9.18%	11.24%	5.54%	10.90%	9.75%
Net Nonoperating Expense Percent (NNEP)	1.98%	8.86%	5.43%	-2.14%	5.83%	6.68%	4.83%	2.27%	2.40%	1.82%
Cost of Revenue to Revenue	52.28%	55.34%	57.29%	54.43%	56.85%	50.98%	54.30%	49.10%	47.37%	47.17%
SG&A Expenses to Revenue	37.04%	34.90%	34.05%	35.02%	28.26%	28.53%	31.62%	34.25%	32.23%	32.98%
R&D to Revenue	5.95%	4.95%	4.24%	4.34%	3.69%	3.12%	3.77%	4.71%	4.29%	4.16%
Operating Expenses to Revenue	43.27%	49.50%	44.90%	39.36%	34.52%	38.56%	35.39%	42.77%	39.28%	40.23%
Earnings before Interest and Taxes (EBIT)	31	-53	-27	60	74	87	73	64	141	152
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	117	36	62	149	183	198	158	165	237	256
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.76	2.49	2.85	5.20	6.68	8.65	7.78	4.35	5.10	4.52
Price to Tangible Book Value (P/TBV)	9.21	7.20	6.01	10.17	13.55	20.87	0.00	0.00	54.93	0.00
Price to Revenue (P/Rev)	2.50	1.97	2.38	4.33	4.61	5.14	6.54	3.29	3.57	3.31
Price to Earnings (P/E)	134.72	0.00	0.00	85.80	81.10	66.35	71.65	75.24	36.17	36.87
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.74%	0.00%	0.00%	1.17%	1.23%	1.51%	1.40%	1.33%	2.76%	2.71%
Enterprise Value to Invested Capital (EV/IC)	2.33	2.06	2.50	4.82	5.47	6.40	4.98	2.99	3.58	3.12
Enterprise Value to Revenue (EV/Rev)	2.79	2.30	2.58	4.41	4.80	5.38	7.13	3.80	3.98	3.79
Enterprise Value to EBITDA (EV/EBITDA)	21.70	57.19	36.70	26.76	25.36	26.88	39.36	22.92	19.67	19.42
Enterprise Value to EBIT (EV/EBIT)	81.62	0.00	0.00	66.81	63.05	61.07	85.16	59.37	32.93	32.68
Enterprise Value to NOPAT (EV/NOPAT)	115.73	0.00	0.00	92.83	74.38	58.65	63.48	68.63	36.56	38.89
Enterprise Value to Operating Cash Flow (EV/OCF)	20.00	17.13	14.30	18.08	29.15	33.64	57.07	21.93	17.05	27.31
Enterprise Value to Free Cash Flow (EV/FCFF)	216.76	43.35	26.51	30.26	116.86	49.70	0.00	98.11	50.92	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.52	0.57	0.43	0.34	0.52	0.65	0.97	1.03	0.94	0.84
Long-Term Debt to Equity	0.49	0.51	0.34	0.08	0.48	0.52	0.94	0.75	0.92	0.83
Financial Leverage	0.31	0.36	0.32	0.17	0.18	0.34	0.58	0.70	0.64	0.62
Leverage Ratio	1.80	1.81	1.75	1.66	1.77	2.03	2.34	2.48	2.42	2.32
Compound Leverage Factor	1.80	1.81	1.75	1.66	1.77	2.03	2.34	2.48	2.42	2.32
Debt to Total Capital	34.12%	36.12%	29.85%	25.21%	34.39%	39.45%	49.16%	50.79%	48.36%	45.70%
Short-Term Debt to Total Capital	1.72%	3.85%	5.79%	19.31%	2.72%	7.94%	1.18%	14.06%	0.74%	0.58%
Long-Term Debt to Total Capital	32.41%	32.27%	24.06%	5.91%	31.68%	31.51%	47.98%	36.73%	47.61%	45.12%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	65.88%	63.88%	70.15%	74.79%	65.61%	60.55%	50.84%	49.21%	51.65%	54.30%
Debt to EBITDA	3.65	11.18	5.05	1.70	1.91	1.93	4.49	4.69	3.24	3.16
Net Debt to EBITDA	2.28	8.03	2.81	0.49	0.99	1.24	3.27	3.12	2.03	2.46
Long-Term Debt to EBITDA	3.47	9.99	4.07	0.40	1.76	1.54	4.38	3.40	3.19	3.12
Debt to NOPAT	19.47	-13.26	-23.19	5.91	5.61	4.21	7.23	14.05	6.01	6.33
Net Debt to NOPAT	12.16	-9.52	-12.91	1.71	2.90	2.70	5.27	9.34	3.78	4.93
Long-Term Debt to NOPAT	18.49	-11.85	-18.69	1.38	5.17	3.37	7.06	10.16	5.92	6.25
Altman Z-Score	3.45	2.97	3.80	6.16	5.86	5.89	4.16	2.77	3.59	3.42
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.96	2.63	2.42	1.35	2.44	2.20	2.74	1.71	3.06	2.56
Quick Ratio	1.62	1.47	1.38	0.86	1.50	1.10	1.26	0.95	1.84	1.28
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	12	48	86	132	40	107	-317	39	91	-162
Operating Cash Flow to CapEx	104.44%	119.75%	217.89%	305.87%	137.14%	494.68%	308.89%	182.31%	251.47%	281.85%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.61	0.65	0.69	0.73	0.77	0.78	0.56	0.54	0.62	0.63
Accounts Receivable Turnover	5.87	6.00	5.72	5.95	5.76	5.64	5.95	6.92	6.90	6.79
Inventory Turnover	2.33	2.53	2.79	2.91	3.10	2.17	1.59	1.58	2.00	2.14
Fixed Asset Turnover	3.07	2.76	2.68	2.76	2.86	3.31	3.70	4.17	4.11	4.21
Accounts Payable Turnover	9.33	11.42	12.28	10.02	9.27	8.83	9.36	8.98	9.05	9.00
Days Sales Outstanding (DSO)	62.23	60.83	63.80	61.36	63.42	64.66	61.38	52.72	52.86	53.77
Days Inventory Outstanding (DIO)	156.73	144.47	130.85	125.27	117.83	168.25	228.94	230.38	182.12	170.40
Days Payable Outstanding (DPO)	39.11	31.97	29.71	36.44	39.36	41.32	39.01	40.66	40.32	40.57
Cash Conversion Cycle (CCC)	179.85	173.32	164.94	150.19	141.89	191.60	251.31	242.44	194.66	183.60
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,093	1,014	915	826	849	832	1,247	1,264	1,299	1,589
Invested Capital Turnover	0.84	0.86	0.92	1.04	1.16	1.18	0.84	0.79	0.91	0.91
Increase / (Decrease) in Invested Capital	10	-79	-100	-89	23	-16	415	17	36	290
Enterprise Value (EV)	2,544	2,087	2,285	3,984	4,643	5,323	6,209	3,778	4,656	4,964
Market Capitalization	2,276	1,794	2,110	3,910	4,462	5,078	5,694	3,263	4,175	4,335
Book Value per Share	$16.04	$14.19	$14.22	$14.08	$13.09	$11.67	$14.40	$14.66	$16.21	$18.90
Tangible Book Value per Share	$4.80	$4.90	$6.75	$7.19	$6.46	$4.84	($1.97)	($0.55)	$1.51	($0.22)
Total Capital	1,254	1,130	1,054	1,006	1,018	970	1,439	1,523	1,584	1,768
Total Debt	428	408	315	254	350	382	708	774	766	808
Total Long-Term Debt	406	365	254	59	322	306	691	559	754	798
Net Debt	267	293	175	74	181	245	515	514	481	629
Capital Expenditures (CapEx)	122	102	73	72	116	32	35	94	109	64
Debt-free, Cash-free Net Working Capital (DFCFNWC)	230	231	220	151	199	268	265	268	245	300
Debt-free Net Working Capital (DFNWC)	391	346	360	331	368	406	457	528	530	479
Net Working Capital (NWC)	369	303	299	136	340	329	440	314	518	469
Net Nonoperating Expense (NNE)	5.08	25	13	-2.66	7.41	14	18	12	12	10
Net Nonoperating Obligations (NNO)	267	293	175	74	181	245	515	514	481	629
Total Depreciation and Amortization (D&A)	86	90	90	89	109	111	85	101	95	104
Debt-free, Cash-free Net Working Capital to Revenue	25.25%	25.40%	24.86%	16.66%	20.53%	27.16%	30.42%	27.03%	20.98%	22.91%
Debt-free Net Working Capital to Revenue	42.90%	38.07%	40.61%	36.59%	38.04%	41.05%	52.51%	53.15%	45.32%	36.57%
Net Working Capital to Revenue	40.53%	33.29%	33.73%	15.10%	35.18%	33.26%	50.55%	31.59%	44.32%	35.79%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.33	($1.09)	($0.51)	$0.86	$1.07	$1.51	$1.57	$0.85	$2.27	$2.32
Adjusted Weighted Average Basic Shares Outstanding	51.53M	50.91M	51.52M	52.76M	51.53M	50.69M	50.69M	51.05M	50.78M	50.71M
Adjusted Diluted Earnings per Share	$0.32	($1.09)	($0.51)	$0.85	$1.04	$1.48	$1.55	$0.84	$2.24	$2.29
Adjusted Weighted Average Diluted Shares Outstanding	52.09M	50.91M	51.52M	53.50M	52.94M	51.82M	51.29M	51.35M	51.42M	51.40M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	51.68M	51.04M	52.46M	52.21M	51.21M	50.39M	50.95M	51.28M	50.54M	50.84M
Normalized Net Operating Profit after Tax (NOPAT)	23	31	27	43	62	135	63	55	127	136
Normalized NOPAT Margin	2.56%	3.37%	3.10%	4.75%	6.45%	13.68%	7.22%	5.54%	10.90%	10.37%
Pre Tax Income Margin	3.42%	-5.88%	-3.10%	6.60%	7.61%	8.82%	8.38%	6.41%	12.10%	11.60%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	231.01%	-109.72%	0.00%	219.43%	290.81%	228.68%	0.00%	0.00%	64.99%	0.00%

This table displays calculated financial ratios and metrics derived from Haemonetics' official financial filings.

Metric	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	7/2/2022	10/1/2022	12/31/2022	4/1/2023	7/1/2023	9/30/2023	12/30/2023	3/30/2024	6/29/2024	9/28/2024	12/28/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	14.41%	24.01%	17.53%	14.87%	19.08%	6.96%	10.14%	12.77%	7.98%	8.59%	3.66%
EBITDA Growth	111.50%	44.66%	17.73%	40.10%	53.11%	-12.76%	1.47%	-3.78%	8.67%	39.06%	21.79%
EBIT Growth	947.54%	106.10%	34.52%	112.87%	102.36%	-20.04%	4.27%	-28.24%	-9.45%	36.16%	13.37%
NOPAT Growth	2,365.39%	106.72%	27.97%	160.21%	77.95%	-29.12%	-3.39%	-17.97%	-23.50%	46.08%	35.91%
Net Income Growth	546.27%	123.46%	41.80%	201.64%	106.48%	-24.97%	-5.17%	-30.68%	-6.50%	35.82%	20.02%
EPS Growth	522.22%	120.69%	42.22%	205.26%	110.53%	-25.00%	-4.69%	-31.03%	-7.50%	37.50%	21.31%
Operating Cash Flow Growth	2,599.58%	100.27%	3.17%	16.99%	-54.55%	13.88%	-100.84%	-19.51%	-243.67%	-50.75%	8,204.81%
Free Cash Flow Firm Growth	96.83%	104.60%	96.56%	4.44%	280.15%	43.49%	-1,831.34%	-6,250.16%	-1,778.60%	-1,777.38%	45.42%
Invested Capital Growth	2.91%	1.45%	3.75%	2.84%	1.39%	-0.05%	22.84%	22.28%	32.79%	38.29%	11.79%
Revenue Q/Q Growth	-1.34%	13.78%	2.63%	-0.29%	2.27%	2.20%	5.68%	2.09%	-2.07%	2.78%	0.88%
EBITDA Q/Q Growth	19.06%	31.34%	4.01%	-13.86%	30.11%	-25.16%	20.98%	-19.26%	46.95%	-4.23%	5.95%
EBIT Q/Q Growth	66.33%	61.05%	2.84%	-22.73%	58.13%	-36.36%	34.10%	-46.82%	99.51%	-4.30%	11.66%
NOPAT Q/Q Growth	96.60%	57.51%	-10.63%	-5.97%	34.45%	-37.26%	21.81%	-20.16%	25.38%	19.80%	13.33%
Net Income Q/Q Growth	104.06%	67.01%	-0.76%	-10.81%	39.68%	-39.31%	25.43%	-34.81%	88.41%	-11.84%	10.83%
EPS Q/Q Growth	100.00%	68.42%	0.00%	-9.38%	37.93%	-40.00%	27.08%	-34.43%	85.00%	-10.81%	12.12%
Operating Cash Flow Q/Q Growth	-38.29%	107.27%	-25.99%	23.59%	-76.03%	419.35%	-100.54%	11,966.85%	-142.79%	278.05%	-10.36%
Free Cash Flow Firm Q/Q Growth	-210.74%	241.81%	-172.67%	70.16%	685.81%	12.95%	-1,078.16%	1.88%	-54.85%	-12.87%	68.17%
Invested Capital Q/Q Growth	4.90%	-1.50%	1.01%	-1.47%	3.42%	-2.90%	24.14%	-1.91%	12.31%	1.12%	0.35%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	54.41%	53.07%	51.98%	51.33%	53.73%	53.59%	52.90%	51.24%	52.03%	54.25%	55.53%
EBITDA Margin	18.64%	21.52%	21.81%	18.84%	23.97%	17.55%	20.09%	16.07%	24.12%	22.48%	23.61%
Operating Margin	11.77%	15.71%	14.18%	11.58%	17.24%	11.10%	13.67%	8.72%	11.83%	14.96%	16.94%
EBIT Margin	9.75%	13.80%	13.83%	10.72%	16.57%	10.32%	13.09%	6.82%	13.90%	12.94%	14.32%
Profit (Net Income) Margin	7.60%	11.16%	10.79%	9.65%	13.18%	7.83%	9.29%	5.93%	11.41%	9.79%	10.76%
Tax Burden Percent	77.97%	80.85%	78.02%	90.06%	79.55%	75.87%	70.96%	86.99%	82.15%	75.68%	75.11%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	22.03%	19.15%	21.98%	9.94%	20.45%	24.14%	29.04%	13.01%	17.85%	24.32%	24.89%
Return on Invested Capital (ROIC)	7.20%	10.62%	9.65%	9.51%	12.52%	7.99%	8.39%	6.88%	8.28%	9.91%	10.19%
ROIC Less NNEP Spread (ROIC-NNEP)	6.50%	9.83%	9.49%	9.04%	12.20%	7.61%	8.16%	5.85%	9.13%	9.12%	9.32%
Return on Net Nonoperating Assets (RNNOA)	5.24%	8.02%	6.82%	5.74%	7.72%	4.63%	5.79%	3.66%	7.00%	6.88%	7.96%
Return on Equity (ROE)	12.44%	18.64%	16.47%	15.25%	20.24%	12.63%	14.17%	10.53%	15.29%	16.79%	18.15%
Cash Return on Invested Capital (CROIC)	3.33%	6.32%	4.66%	7.14%	9.55%	10.39%	-11.40%	-11.21%	-20.63%	-23.75%	-2.83%
Operating Return on Assets (OROA)	5.54%	8.16%	8.42%	6.60%	10.68%	6.60%	8.16%	4.32%	8.23%	7.76%	8.31%
Return on Assets (ROA)	4.32%	6.60%	6.57%	5.95%	8.49%	5.01%	5.79%	3.76%	6.76%	5.88%	6.25%
Return on Common Equity (ROCE)	12.44%	18.64%	16.47%	15.25%	20.24%	12.63%	14.17%	10.53%	15.29%	16.79%	18.15%
Return on Equity Simple (ROE_SIMPLE)	8.79%	11.80%	12.34%	0.00%	15.80%	14.35%	13.42%	0.00%	12.69%	14.09%	14.34%
Net Operating Profit after Tax (NOPAT)	24	38	34	32	43	27	33	26	33	39	44
NOPAT Margin	9.17%	12.70%	11.06%	10.43%	13.71%	8.42%	9.70%	7.59%	9.71%	11.32%	12.72%
Net Nonoperating Expense Percent (NNEP)	0.71%	0.79%	0.15%	0.48%	0.32%	0.38%	0.23%	1.02%	-0.84%	0.79%	0.87%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	1.80%	-	-	-	2.08%
Cost of Revenue to Revenue	45.59%	46.93%	48.02%	48.67%	46.27%	46.41%	47.10%	48.76%	47.97%	45.75%	44.47%
SG&A Expenses to Revenue	35.27%	30.94%	31.01%	32.11%	30.03%	36.24%	33.22%	35.45%	32.20%	30.95%	30.54%
R&D to Revenue	4.17%	3.66%	4.16%	5.14%	4.06%	3.98%	3.95%	4.62%	4.30%	4.78%	4.54%
Operating Expenses to Revenue	42.64%	37.36%	37.81%	39.75%	36.49%	42.49%	39.22%	42.52%	40.21%	39.29%	38.59%
Earnings before Interest and Taxes (EBIT)	25	41	42	33	52	33	44	23	47	45	50
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	49	64	67	57	75	56	68	55	81	78	82
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.48	5.21	5.13	5.10	4.98	5.08	4.60	4.52	4.65	4.65	4.30
Price to Tangible Book Value (P/TBV)	2,160.19	0.00	156.19	54.93	32.96	25.56	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	3.36	3.51	3.52	3.57	3.53	3.67	3.42	3.31	3.15	3.00	2.84
Price to Earnings (P/E)	50.98	44.15	41.57	36.17	31.51	35.41	34.28	36.87	36.61	32.99	29.95
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.96%	2.27%	2.41%	2.76%	3.17%	2.82%	2.92%	2.71%	2.73%	3.03%	3.34%
Enterprise Value to Invested Capital (EV/IC)	3.02	3.35	3.43	3.58	3.56	3.80	3.10	3.12	2.85	2.78	2.65
Enterprise Value to Revenue (EV/Rev)	3.91	4.04	4.01	3.98	3.92	4.00	3.95	3.79	3.81	3.68	3.49
Enterprise Value to EBITDA (EV/EBITDA)	21.04	20.81	20.54	19.67	18.21	19.47	19.64	19.42	19.40	17.65	16.07
Enterprise Value to EBIT (EV/EBIT)	43.49	38.63	36.45	32.93	28.55	31.10	31.14	32.68	34.60	31.54	29.13
Enterprise Value to NOPAT (EV/NOPAT)	49.51	43.52	41.88	36.56	32.78	36.72	37.50	38.89	43.09	38.40	33.70
Enterprise Value to Operating Cash Flow (EV/OCF)	18.56	16.86	17.30	17.05	19.12	18.89	25.42	27.31	37.60	58.98	37.14
Enterprise Value to Free Cash Flow (EV/FCFF)	92.22	53.43	74.97	50.92	37.51	36.54	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.00	1.12	0.99	0.94	0.88	0.85	0.92	0.84	1.35	1.39	1.35
Long-Term Debt to Equity	0.99	1.04	0.98	0.92	0.87	0.84	0.91	0.83	1.35	1.39	1.35
Financial Leverage	0.81	0.82	0.72	0.64	0.63	0.61	0.71	0.62	0.77	0.75	0.85
Leverage Ratio	2.50	2.57	2.46	2.42	2.31	2.39	2.37	2.32	2.54	2.56	2.56
Compound Leverage Factor	2.50	2.57	2.46	2.42	2.31	2.39	2.37	2.32	2.54	2.56	2.56
Debt to Total Capital	49.99%	52.87%	49.70%	48.36%	46.94%	46.03%	48.00%	45.70%	57.47%	58.23%	57.46%
Short-Term Debt to Total Capital	0.44%	3.76%	0.64%	0.74%	0.83%	0.82%	0.76%	0.58%	0.24%	0.26%	0.24%
Long-Term Debt to Total Capital	49.54%	49.11%	49.06%	47.61%	46.11%	45.21%	47.24%	45.12%	57.23%	57.97%	57.22%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	50.01%	47.13%	50.30%	51.65%	53.06%	53.97%	52.00%	54.30%	42.53%	41.77%	42.54%
Debt to EBITDA	4.04	3.89	3.48	3.24	2.91	3.00	3.41	3.16	4.67	4.32	4.10
Net Debt to EBITDA	2.91	2.74	2.46	2.03	1.83	1.62	2.65	2.46	3.35	3.26	3.03
Long-Term Debt to EBITDA	4.01	3.61	3.44	3.19	2.86	2.94	3.36	3.12	4.65	4.30	4.08
Debt to NOPAT	9.51	8.13	7.10	6.01	5.24	5.65	6.51	6.33	10.37	9.39	8.60
Net Debt to NOPAT	6.86	5.73	5.03	3.78	3.29	3.05	5.06	4.93	7.45	7.10	6.35
Long-Term Debt to NOPAT	9.43	7.55	7.01	5.92	5.15	5.55	6.41	6.25	10.33	9.35	8.56
Altman Z-Score	3.09	3.11	3.32	3.41	3.61	3.68	3.21	3.22	2.68	2.61	2.62
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.81	2.73	3.11	3.06	3.38	3.28	2.92	2.56	3.76	3.49	3.97
Quick Ratio	2.00	1.57	1.79	1.84	1.95	1.99	1.55	1.28	2.10	1.87	2.10
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-13	19	-14	-4.15	24	27	-269	-263	-408	-461	-147
Operating Cash Flow to CapEx	93.38%	300.99%	385.95%	442.14%	262.21%	1,153.41%	-3.77%	701.57%	0.00%	528.16%	527.62%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.57	0.59	0.61	0.62	0.64	0.64	0.62	0.63	0.59	0.60	0.58
Accounts Receivable Turnover	7.35	6.93	6.72	6.90	7.53	7.17	6.47	6.79	7.05	7.02	6.49
Inventory Turnover	1.61	1.76	1.90	2.00	2.04	2.17	2.14	2.14	1.91	1.93	1.93
Fixed Asset Turnover	4.08	4.08	4.09	4.11	4.11	4.03	4.02	4.21	4.40	4.48	4.54
Accounts Payable Turnover	9.09	9.56	9.29	9.05	8.50	8.28	9.92	9.00	8.19	8.64	10.71
Days Sales Outstanding (DSO)	49.69	52.68	54.31	52.86	48.46	50.92	56.42	53.77	51.80	51.99	56.28
Days Inventory Outstanding (DIO)	226.75	207.13	191.87	182.12	178.92	168.19	170.75	170.40	190.64	188.96	188.74
Days Payable Outstanding (DPO)	40.16	38.19	39.28	40.32	42.92	44.08	36.79	40.57	44.59	42.27	34.08
Cash Conversion Cycle (CCC)	236.28	221.62	206.90	194.66	184.46	175.04	190.39	183.60	197.85	198.69	210.94
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,325	1,306	1,319	1,299	1,344	1,305	1,620	1,589	1,785	1,805	1,811
Invested Capital Turnover	0.79	0.84	0.87	0.91	0.91	0.95	0.86	0.91	0.85	0.88	0.80
Increase / (Decrease) in Invested Capital	37	19	48	36	18	-0.67	301	290	441	500	191
Enterprise Value (EV)	4,007	4,376	4,523	4,656	4,782	4,954	5,016	4,964	5,085	5,010	4,800
Market Capitalization	3,452	3,799	3,980	4,175	4,303	4,543	4,339	4,335	4,206	4,084	3,896
Book Value per Share	$15.02	$14.21	$15.33	$16.21	$17.11	$17.62	$18.59	$18.90	$17.81	$17.17	$18.06
Tangible Book Value per Share	$0.03	($0.56)	$0.50	$1.51	$2.58	$3.51	($0.81)	($0.22)	($3.99)	($4.40)	($3.27)
Total Capital	1,540	1,547	1,543	1,584	1,630	1,656	1,814	1,768	2,129	2,104	2,132
Total Debt	770	818	767	766	765	762	871	808	1,224	1,225	1,225
Total Long-Term Debt	763	760	757	754	751	749	857	798	1,218	1,220	1,220
Net Debt	555	577	543	481	479	411	677	629	879	926	904
Capital Expenditures (CapEx)	45	29	17	18	7.28	8.59	14	9.13	-15	9.24	8.30
Debt-free, Cash-free Net Working Capital (DFCFNWC)	299	271	265	245	293	264	323	300	379	388	437
Debt-free Net Working Capital (DFNWC)	514	512	489	530	578	615	517	479	724	687	758
Net Working Capital (NWC)	507	454	479	518	565	602	503	469	719	682	753
Net Nonoperating Expense (NNE)	4.11	4.59	0.82	2.37	1.65	1.87	1.38	5.68	-5.71	5.29	6.84
Net Nonoperating Obligations (NNO)	555	577	543	481	479	411	677	629	879	926	904
Total Depreciation and Amortization (D&A)	23	23	24	25	23	23	24	32	34	33	32
Debt-free, Cash-free Net Working Capital to Revenue	29.16%	24.97%	23.50%	20.98%	24.01%	21.31%	25.43%	22.91%	28.43%	28.51%	31.81%
Debt-free Net Working Capital to Revenue	50.11%	47.23%	43.34%	45.32%	47.45%	49.64%	40.70%	36.57%	54.25%	50.50%	55.17%
Net Working Capital to Revenue	49.44%	41.86%	42.45%	44.32%	46.34%	48.54%	39.62%	35.79%	53.87%	50.10%	54.80%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.39	$0.65	$0.65	$0.58	$0.81	$0.49	$0.62	$0.40	$0.75	$0.66	$0.75
Adjusted Weighted Average Basic Shares Outstanding	51.22M	50.95M	50.51M	50.78M	50.54M	50.73M	50.77M	50.71M	50.94M	50.90M	50.29M
Adjusted Diluted Earnings per Share	$0.38	$0.64	$0.64	$0.58	$0.80	$0.48	$0.61	$0.40	$0.74	$0.66	$0.74
Adjusted Weighted Average Diluted Shares Outstanding	51.68M	51.56M	51.22M	51.42M	51.34M	51.40M	51.45M	51.40M	51.56M	51.24M	50.64M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	51.32M	50.61M	50.45M	50.54M	50.71M	50.74M	50.79M	50.84M	51.18M	50.22M	50.24M
Normalized Net Operating Profit after Tax (NOPAT)	24	38	34	32	43	27	33	26	33	39	44
Normalized NOPAT Margin	9.17%	12.70%	11.06%	10.43%	13.71%	8.42%	9.70%	7.59%	9.71%	11.32%	12.72%
Pre Tax Income Margin	9.75%	13.80%	13.83%	10.72%	16.57%	10.32%	13.09%	6.82%	13.90%	12.94%	14.32%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	87.16%	78.32%	64.99%	0.00%	0.00%	0.00%	0.00%	0.00%	60.58%	57.66%

Frequently Asked Questions About Haemonetics' Financials

When does Haemonetics's fiscal year end?

According to the most recent income statement we have on file, Haemonetics' financial year ends in March. Their financial year 2024 ended on March 30, 2024.

How has Haemonetics' net income changed over the last 9 years?

Haemonetics' net income appears to be on an upward trend, with a most recent value of $117.56 million in 2024, rising from $16.90 million in 2015. The previous period was $115.40 million in 2023. See Haemonetics' forecast for analyst expectations on what’s next for the company.

What is Haemonetics's operating income?

Haemonetics's total operating income in 2024 was $164.88 million, based on the following breakdown:

Total Gross Profit: $691.55 million
Total Operating Expenses: $526.67 million

How has Haemonetics revenue changed over the last 9 years?

Over the last 9 years, Haemonetics' total revenue changed from $910.37 million in 2015 to $1.31 billion in 2024, a change of 43.8%.

How much debt does Haemonetics have?

Haemonetics' total liabilities were at $1.24 billion at the end of 2024, a 10.6% increase from 2023, and a 87.4% increase since 2015.

How much cash does Haemonetics have?

In the past 9 years, Haemonetics' cash and equivalents has ranged from $115.12 million in 2016 to $284.47 million in 2023, and is currently $178.80 million as of their latest financial filing in 2024.

How has Haemonetics' book value per share changed over the last 9 years?

Over the last 9 years, Haemonetics' book value per share changed from 16.04 in 2015 to 18.90 in 2024, a change of 17.8%.

Related Companies

This page (NYSE:HAE) was last updated on 5/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Haemonetics (HAE) Financials

Frequently Asked Questions About Haemonetics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Haemonetics (HAE) Financials

Annual Income Statements for Haemonetics

Quarterly Income Statements for Haemonetics

Annual Cash Flow Statements for Haemonetics

Quarterly Cash Flow Statements for Haemonetics

Annual Balance Sheets for Haemonetics

Quarterly Balance Sheets for Haemonetics

Annual Metrics and Ratios for Haemonetics

Quarterly Metrics and Ratios for Haemonetics

Frequently Asked Questions About Haemonetics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools